Effects of the oral administration of mosapride citrate on capsule endoscopy completion rate

Yosuke Ida, Naoki Hosoe, Hiroyuki Imaeda, Rieko Bessho, Riko Ichikawa, Makoto Naganuma, Takanori Kanai, Toshifumi Hibi, Haruhiko Ogata

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background/Aims: In capsule endoscopy (CE), the capsule does not always reach the cecum within its battery life, which may reduce its diagnostic yield. We evaluated the effect of mosapride citrate, a 5-hydroxytryptamine-4 agonist that increases gastrointestinal motility, on CE completion. Methods: In a retrospective study, we performed univariate and multivariate analyses for 232 CE procedures performed at our hospital. To identify factors that affect CE completion, the following data were systematically collected: gender, age, gastric transit time (GTT), nonsteroidal anti-inflammatory drug administration, previous abdominal surgery, hospitalization, use of a polyethylene glycol solution, use of mosapride citrate (10 mg), body mass index (BMI), and total recording time. Results: The univariate analysis showed that oral mosapride citrate, GTT, and BMI were associated with improved CE completion. Multivariate analyses showed that oral mosapride citrate (odds ratio [OR], 1.99; 95% confidence interval [CI], 1.01 to 3.91) and GTT (OR, 2.34; 95% CI, 1.13 to 4.87) were significant factors for improving the CE completion. Oral mosapride citrate significantly shortened the GTT and small bowel transit time (SBTT). Conclusions: Oral mosapride citrate reduced the GTT and SBTT during CE and improved the CE completion rate.

Original languageEnglish
Pages (from-to)339-343
Number of pages5
JournalGut and Liver
Volume6
Issue number3
DOIs
Publication statusPublished - 2012 Jul

Fingerprint

Capsule Endoscopy
Oral Administration
Stomach
Body Mass Index
Multivariate Analysis
Odds Ratio
Confidence Intervals
Serotonin Receptor Agonists
Gastrointestinal Motility
Cecum
mosapride
Capsules
Hospitalization
Anti-Inflammatory Agents
Retrospective Studies

Keywords

  • Capsule endoscopy
  • Mosapride
  • Prokinetics

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Effects of the oral administration of mosapride citrate on capsule endoscopy completion rate. / Ida, Yosuke; Hosoe, Naoki; Imaeda, Hiroyuki; Bessho, Rieko; Ichikawa, Riko; Naganuma, Makoto; Kanai, Takanori; Hibi, Toshifumi; Ogata, Haruhiko.

In: Gut and Liver, Vol. 6, No. 3, 07.2012, p. 339-343.

Research output: Contribution to journalArticle

@article{049e02acd883467981ee3d568450d976,
title = "Effects of the oral administration of mosapride citrate on capsule endoscopy completion rate",
abstract = "Background/Aims: In capsule endoscopy (CE), the capsule does not always reach the cecum within its battery life, which may reduce its diagnostic yield. We evaluated the effect of mosapride citrate, a 5-hydroxytryptamine-4 agonist that increases gastrointestinal motility, on CE completion. Methods: In a retrospective study, we performed univariate and multivariate analyses for 232 CE procedures performed at our hospital. To identify factors that affect CE completion, the following data were systematically collected: gender, age, gastric transit time (GTT), nonsteroidal anti-inflammatory drug administration, previous abdominal surgery, hospitalization, use of a polyethylene glycol solution, use of mosapride citrate (10 mg), body mass index (BMI), and total recording time. Results: The univariate analysis showed that oral mosapride citrate, GTT, and BMI were associated with improved CE completion. Multivariate analyses showed that oral mosapride citrate (odds ratio [OR], 1.99; 95{\%} confidence interval [CI], 1.01 to 3.91) and GTT (OR, 2.34; 95{\%} CI, 1.13 to 4.87) were significant factors for improving the CE completion. Oral mosapride citrate significantly shortened the GTT and small bowel transit time (SBTT). Conclusions: Oral mosapride citrate reduced the GTT and SBTT during CE and improved the CE completion rate.",
keywords = "Capsule endoscopy, Mosapride, Prokinetics",
author = "Yosuke Ida and Naoki Hosoe and Hiroyuki Imaeda and Rieko Bessho and Riko Ichikawa and Makoto Naganuma and Takanori Kanai and Toshifumi Hibi and Haruhiko Ogata",
year = "2012",
month = "7",
doi = "10.5009/gnl.2012.6.3.339",
language = "English",
volume = "6",
pages = "339--343",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "3",

}

TY - JOUR

T1 - Effects of the oral administration of mosapride citrate on capsule endoscopy completion rate

AU - Ida, Yosuke

AU - Hosoe, Naoki

AU - Imaeda, Hiroyuki

AU - Bessho, Rieko

AU - Ichikawa, Riko

AU - Naganuma, Makoto

AU - Kanai, Takanori

AU - Hibi, Toshifumi

AU - Ogata, Haruhiko

PY - 2012/7

Y1 - 2012/7

N2 - Background/Aims: In capsule endoscopy (CE), the capsule does not always reach the cecum within its battery life, which may reduce its diagnostic yield. We evaluated the effect of mosapride citrate, a 5-hydroxytryptamine-4 agonist that increases gastrointestinal motility, on CE completion. Methods: In a retrospective study, we performed univariate and multivariate analyses for 232 CE procedures performed at our hospital. To identify factors that affect CE completion, the following data were systematically collected: gender, age, gastric transit time (GTT), nonsteroidal anti-inflammatory drug administration, previous abdominal surgery, hospitalization, use of a polyethylene glycol solution, use of mosapride citrate (10 mg), body mass index (BMI), and total recording time. Results: The univariate analysis showed that oral mosapride citrate, GTT, and BMI were associated with improved CE completion. Multivariate analyses showed that oral mosapride citrate (odds ratio [OR], 1.99; 95% confidence interval [CI], 1.01 to 3.91) and GTT (OR, 2.34; 95% CI, 1.13 to 4.87) were significant factors for improving the CE completion. Oral mosapride citrate significantly shortened the GTT and small bowel transit time (SBTT). Conclusions: Oral mosapride citrate reduced the GTT and SBTT during CE and improved the CE completion rate.

AB - Background/Aims: In capsule endoscopy (CE), the capsule does not always reach the cecum within its battery life, which may reduce its diagnostic yield. We evaluated the effect of mosapride citrate, a 5-hydroxytryptamine-4 agonist that increases gastrointestinal motility, on CE completion. Methods: In a retrospective study, we performed univariate and multivariate analyses for 232 CE procedures performed at our hospital. To identify factors that affect CE completion, the following data were systematically collected: gender, age, gastric transit time (GTT), nonsteroidal anti-inflammatory drug administration, previous abdominal surgery, hospitalization, use of a polyethylene glycol solution, use of mosapride citrate (10 mg), body mass index (BMI), and total recording time. Results: The univariate analysis showed that oral mosapride citrate, GTT, and BMI were associated with improved CE completion. Multivariate analyses showed that oral mosapride citrate (odds ratio [OR], 1.99; 95% confidence interval [CI], 1.01 to 3.91) and GTT (OR, 2.34; 95% CI, 1.13 to 4.87) were significant factors for improving the CE completion. Oral mosapride citrate significantly shortened the GTT and small bowel transit time (SBTT). Conclusions: Oral mosapride citrate reduced the GTT and SBTT during CE and improved the CE completion rate.

KW - Capsule endoscopy

KW - Mosapride

KW - Prokinetics

UR - http://www.scopus.com/inward/record.url?scp=84865403986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865403986&partnerID=8YFLogxK

U2 - 10.5009/gnl.2012.6.3.339

DO - 10.5009/gnl.2012.6.3.339

M3 - Article

VL - 6

SP - 339

EP - 343

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 3

ER -